Id: acc0498
Group: 1sens
Protein: ATR
Gene Symbol: ATR
Protein Id: Q13535
Protein Name: ATR_HUMAN
PTM: phosphorylation
Site: Ser428
Site Sequence: NLSSNSDGISPKRRRLSSSLN
Disease Category: Cancer
Disease: Head and Neck Cancer
Disease Subtype: HNSCC
Disease Cellline: SCC61
Disease Info:
Drug: Cisplatin
Drug Info: "Cisplatin is a platinum-based chemotherapeutic agent widely used in the treatment of various malignancies, including ovarian, bladder, testicular, and non-small cell lung cancers, by forming DNA cross-links to interfere with replication and repair, thereby inhibiting cancer cell growth and proliferation."
Effect: modulate
Effect Info: Drugs inhibit protein phosphorylation to suppress tumors.
Note:
Score: 4.0
Pubmed(PMID): 27863405
Sentence Index:
Sentence:

Sequence & Structure:

MGEHGLELASMIPALRELGSATPEEYNTVVQKPRQILCQFIDRILTDVNVVAVELVKKTDSQPTSVMLLDFIQHIMKSSPLMFVNVSGSHEAKGSCIEFSNWIITRLLRIAATPSCHLLHKKICEVICSLLFLFKSKSPAIFGVLTKELLQLFEDLVYLHRRNVMGHAVEWPVVMSRFLSQLDEHMGYLQSAPLQLMSMQNLEFIEVTLLMVLTRIIAIVFFRRQELLLWQIGCVLLEYGSPKIKSLAISFLTELFQLGGLPAQPASTFFSSFLELLKHLVEMDTDQLKLYEEPLSKLIKTLFPFEAEAYRNIEPVYLNMLLEKLCVMFEDGVLMRLKSDLLKAALCHLLQYFLKFVPAGYESALQVRKVYVRNICKALLDVLGIEVDAEYLLGPLYAALKMESMEIIEEIQCQTQQENLSSNSDGISPKRRRLSSSLNPSKRAPKQTEEIKHVDMNQKSILWSALKQKAESLQISLEYSGLKNPVIEMLEGIAVVLQLTALCTVHCSHQNMNCRTFKDCQHKSKKKPSVVITWMSLDFYTKVLKSCRSLLESVQKLDLEATIDKVVKIYDALIYMQVNSSFEDHILEDLCGMLSLPWIYSHSDDGCLKLTTFAANLLTLSCRISDSYSPQAQSRCVFLLTLFPRRIFLEWRTAVYNWALQSSHEVIRASCVSGFFILLQQQNSCNRVPKILIDKVKDDSDIVKKEFASILGQLVCTLHGMFYLTSSLTEPFSEHGHVDLFCRNLKATSQHECSSSQLKASVCKPFLFLLKKKIPSPVKLAFIDNLHHLCKHLDFREDETDVKAVLGTLLNLMEDPDKDVRVAFSGNIKHILESLDSEDGFIKELFVLRMKEAYTHAQISRNNELKDTLILTTGDIGRAAKGDLVPFALLHLLHCLLSKSASVSGAAYTEIRALVAAKSVKLQSFFSQYKKPICQFLVESLHSSQMTALPNTPCQNADVRKQDVAHQREMALNTLSEIANVFDFPDLNRFLTRTLQVLLPDLAAKASPAASALIRTLGKQLNVNRREILINNFKYIFSHLVCSCSKDELERALHYLKNETEIELGSLLRQDFQGLHNELLLRIGEHYQQVFNGLSILASFASSDDPYQGPRDIISPELMADYLQPKLLGILAFFNMQLLSSSVGIEDKKMALNSLMSLMKLMGPKHVSSVRVKMMTTLRTGLRFKDDFPELCCRAWDCFVRCLDHACLGSLLSHVIVALLPLIHIQPKETAAIFHYLIIENRDAVQDFLHEIYFLPDHPELKKIKAVLQEYRKETSESTDLQTTLQLSMKAIQHENVDVRIHALTSLKETLYKNQEKLIKYATDSETVEPIISQLVTVLLKGCQDANSQARLLCGECLGELGAIDPGRLDFSTTETQGKDFTFVTGVEDSSFAYGLLMELTRAYLAYADNSRAQDSAAYAIQELLSIYDCREMETNGPGHQLWRRFPEHVREILEPHLNTRYKSSQKSTDWSGVKKPIYLSKLGSNFAEWSASWAGYLITKVRHDLASKIFTCCSIMMKHDFKVTIYLLPHILVYVLLGCNQEDQQEVYAEIMAVLKHDDQHTINTQDIASDLCQLSTQTVFSMLDHLTQWARHKFQALKAEKCPHSKSNRNKVDSMVSTVDYEDYQSVTRFLDLIPQDTLAVASFRSKAYTRAVMHFESFITEKKQNIQEHLGFLQKLYAAMHEPDGVAGVSAIRKAEPSLKEQILEHESLGLLRDATACYDRAIQLEPDQIIHYHGVVKSMLGLGQLSTVITQVNGVHANRSEWTDELNTYRVEAAWKLSQWDLVENYLAADGKSTTWSVRLGQLLLSAKKRDITAFYDSLKLVRAEQIVPLSAASFERGSYQRGYEYIVRLHMLCELEHSIKPLFQHSPGDSSQEDSLNWVARLEMTQNSYRAKEPILALRRALLSLNKRPDYNEMVGECWLQSARVARKAGHHQTAYNALLNAGESRLAELYVERAKWLWSKGDVHQALIVLQKGVELCFPENETPPEGKNMLIHGRAMLLVGRFMEETANFESNAIMKKYKDVTACLPEWEDGHFYLAKYYDKLMPMVTDNKMEKQGDLIRYIVLHFGRSLQYGNQFIYQSMPRMLTLWLDYGTKAYEWEKAGRSDRVQMRNDLGKINKVITEHTNYLAPYQFLTAFSQLISRICHSHDEVFVVLMEIIAKVFLAYPQQAMWMMTAVSKSSYPMRVNRCKEILNKAIHMKKSLEKFVGDATRLTDKLLELCNKPVDGSSSTLSMSTHFKMLKKLVEEATFSEILIPLQSVMIPTLPSILGTHANHASHEPFPGHWAYIAGFDDMVEILASLQKPKKISLKGSDGKFYIMMCKPKDDLRKDCRLMEFNSLINKCLRKDAESRRRELHIRTYAVIPLNDECGIIEWVNNTAGLRPILTKLYKEKGVYMTGKELRQCMLPKSAALSEKLKVFREFLLPRHPPIFHEWFLRTFPDPTSWYSSRSAYCRSTAVMSMVGYILGLGDRHGENILFDSLTGECVHVDFNCLFNKGETFEVPEIVPFRLTHNMVNGMGPMGTEGLFRRACEVTMRLMRDQREPLMSVLKTFLHDPLVEWSKPVKGHSKAPLNETGEVVNEKAKTHVLDIEQRLQGVIKTRNRVTGLPLSIEGHVHYLIQEATDENLLCQMYLGWTPYM

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 3 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
ATR BERZOSERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting metastatic prostate cancer ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting adenocarcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting carcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Recruiting breast carcinoma ClinicalTrials
ATR BERZOSERTIB Serine-protein kinase ATR inhibitor 2 Recruiting leiomyosarcoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting neoplasm ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Recruiting osteosarcoma ClinicalTrials
ATR BERZOSERTIB Serine-protein kinase ATR inhibitor 2 Completed small cell lung carcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Recruiting small cell lung carcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting squamous cell carcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Completed small cell lung carcinoma ClinicalTrials
ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting melanoma ClinicalTrials
ATR BERZOSERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting ovarian carcinoma ClinicalTrials
ATR BERZOSERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting prostate carcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Recruiting breast neoplasm ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Suspended cholangiocarcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Recruiting triple-negative breast cancer ClinicalTrials
ATR BERZOSERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting bladder transitional cell carcinoma ClinicalTrials
ATR BERZOSERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting ureter urothelial carcinoma ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting bile duct cancer ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Terminated cancer ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Active, not recruiting breast cancer ClinicalTrials
ATR CERALASERTIB Serine-protein kinase ATR inhibitor 2 Recruiting breast cancer ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
ATR-Ser428
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.701
GBM
HNSC 0.71
LUAD
LUSC -1.416
non_ccRCC
PDAC
UCEC 0.004

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 428 U Colorectal carcinoma Phosphorylation 35999268

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: